A Pilot Feasibility and Efficacy Study Assessing Tibetan Medicine for Metastatic Breast Cancer
First formal FDA approved study of Tibetan Medicine and the treatment of cancer.
Dr Yeshi Dhonden, Chief Medical Advisor
Dr. Lobsang Tenzin, Medical Advisor
Marsha Woolf, Clinical Director
Introduction
Breast cancer is a national epidemic. The rate of breast cancer in the United States has continued to grow unabated. Despite the fact that many new drugs, surgical and radiation techniques have been developed, they have not had enough impact on impeding the progress of this life threatening condition.
Dr. Yeshi Dhonden, a renowned traditional Tibetan doctor, and one of the foremost living authorities on Tibetan Medicine, has successfully treated breast cancer in thousands of women in both India and throughout the world for over forty-five years. The rate of survival for women treated with the ancient herbal therapies he has revised and developed appears to be much higher than those receiving allopathic cancer treatments alone. Unfortunately, these therapies are virtually unknown in the West, where the epidemic is out of control. It was the objective of Dr. Dhonden and the Menla Tibetan Medical Institute, Marsha Woolf, director, to prove these results in scientifically conducted clinical trials and to make Tibetan Medicine available to women in the United States and elsewhere.
In order to more firmly establish the use of these therapies in the West, Menla undertook a research project in collaboration with the University of California, San Francisco. The purpose was to prove non-toxicity and substantiate the efficacy of Tibetan Medicine in the treatment of stage IV Metastatic Breast Cancer. To our knowledge, this was the first formal FDA approved study of its kind in the world. We are certain that it contributed to a much greater awareness of this very effective approach to healing.
Please contact us if you are interested in supporting our research so that we may bring hope to the millions who are suffering with this devastating disease.
We would like to acknowledge and remember Dr. Helene Smith, California Pacific Medical Center, for her pioneering efforts in developing this project.